# Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

> **NCT04031833** · PHASE1,PHASE2 · COMPLETED · sponsor: **Matinas BioPharma Nanotechnologies, Inc.** · enrollment: 178 (actual)

## Conditions studied

- Cryptococcal Meningitis

## Interventions

- **DRUG:** MAT2203
- **DRUG:** Amphotericin B

## Key facts

- **NCT ID:** NCT04031833
- **Lead sponsor:** Matinas BioPharma Nanotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-24
- **Primary completion:** 2022-11-14
- **Final completion:** 2023-02-15
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2023-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04031833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04031833, "Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04031833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*